Figure 3
Validation of differentially expressed genes by immunohistochemistry. (A) Representative H&E staining of a poorly differentiated serous papillary carcinoma and a benign endometrioid adenomyofibroma. (B) Staining of the same tumours with anti-CD24 antibody. The benign tumour showed weak staining whereas the malignant tumour showed moderate to strong signal. Areas of intense staining indicated by arrows. (C) Staining of both tumours with anti-SPARCL1 antibody. The benign endometrioid adenomyofibroma exhibited moderate to intense staining while the serous papillary carcinoma showed moderate staining with more prominent areas.
